menu search

KDNY / JAZZ Q4 Earnings Top, Sales Ride on New & Acquired Drugs

JAZZ Q4 Earnings Top, Sales Ride on New & Acquired Drugs
JAZZ's product revenues grow in the fourth quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. Read More
Posted: Mar 2 2022, 10:42
Author Name: Zacks Investment Research
Views: 111811

KDNY News  

Chief Scientific Officer Andrew King Sells 1,168 Shares of Chinook Therapeutics Inc (KDNY)

By GuruFocus
August 2, 2023

Chief Scientific Officer Andrew King Sells 1,168 Shares of Chinook Therapeutics Inc (KDNY)

On August 1, 2023, Andrew King, the Chief Scientific Officer of Chinook Therapeutics Inc ( KDNY , Financial), sold 1,168 shares of the company. This m more_horizontal

2 Surging Healthcare Stocks With More Fuel in the Tank

By The Motley Fool
June 20, 2023

2 Surging Healthcare Stocks With More Fuel in the Tank

Shares of two biotech stocks are way up over the past month thanks to impressive clinical trial results for the drugs they're developing. Chinook Ther more_horizontal

Novartis Stock Screams Value After Chinook Therapeutics Buyout

By MarketBeat
June 13, 2023

Novartis Stock Screams Value After Chinook Therapeutics Buyout

That value proposition took a huge step forward on Monday when Novartis announced a $3.2 billion acquisition of Seattle-based biotechnology company Ch more_horizontal

KDNY Stock Alert: Why Short Seller Muddy Waters Is Betting Against Chinook

By InvestorPlace
June 12, 2023

KDNY Stock Alert: Why Short Seller Muddy Waters Is Betting Against Chinook

Chinook Therapeutics (NASDAQ: KDNY ) has been surging all day. Why? KDNY stock surged on news that multinational pharmaceutical giant Novartis (NYSE: more_horizontal

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

By GlobeNewsWire
June 12, 2023

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

SEATTLE, June 12, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, developmen more_horizontal

Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts say

By Market Watch
June 12, 2023

Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts say

In light of a Novartis NVS, -0.94% deal to acquire Chinook Therapeutics Inc. KDNY, +58.09%, which is developing treatments for a rare kidney disease, more_horizontal

Why Shares of Chinook Therapeutics Skyrocketed On Monday

By The Motley Fool
June 12, 2023

Why Shares of Chinook Therapeutics Skyrocketed On Monday

Novartis has agreed to buy out Chinook in a deal that could be worth $3.5 billion. Chinook is a clinical-stage biotech. more_horizontal

Chinook Therapeutics Shares Soar on Novartis Purchase

By Investopedia
June 12, 2023

Chinook Therapeutics Shares Soar on Novartis Purchase

Novartis agreed to buy Chinook Therapeutics for up to $3.5 billion. more_horizontal


Search within

Pages Search Results: